Veeva Systems Inc Class A

Veeva Systems reported a record second quarter for fiscal 2027, with total revenue of $928 million and non-GAAP operating income of $416 million, both exceeding guidance. The company achieved its best-ever CRM quarter, with two TOP20 biopharma customers, Lilly and Biogen, selecting Vault CRM, bringing the total to 12 of TOP20. Veeva Falcon, its agentic AI product, is generating high customer interest, with early adopters showing promising results and faster implementation. Commercial subscription revenue grew 13% year-over-year, with broad-based strength across CRM, content, data, and Crossix. The company also highlighted progress with its Aspen product, priced at $50 per user per month, and its partnership with IQVIA, which CEO Peter Gassner called one of the best things to happen to Veeva in the past 12 months.

Veeva Systems reported quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.22 per share, and compared to $1.99 per share a year ago. Revenue for the quarter ended July 2026 was $927.96 million, surpassing the consensus estimate by 2.64% and up from $789.08 million in the prior year. The company has exceeded EPS and revenue estimates in each of the last four quarters. Veeva shares have gained about 10.6% since the start of the year, underperforming the S&P 500's 12.2% gain. The current consensus EPS estimate for the coming quarter is $2.28 on $918.02 million in revenues, and for the fiscal year it is $9.05 on $3.64 billion in revenues.

Veeva Systems announced that Biogen has committed to Veeva Vault CRM globally. The unified commercial platform is intended to help speed the delivery of medicines to patients. Tom Schwenger, president and CCO at Veeva, said Vault CRM will serve as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives. Guy Hadari, senior vice president and global CIO at Biogen, said the companies share a deep commitment to customer experience and innovation, and Biogen is excited to expand its strategic partnership with Veeva by moving to Vault CRM. Vault CRM is part of the Vault CRM Suite, which includes the Agentic Call Report to generate Commercial Evidence.

The analyst-derived fair value estimate for Veeva Systems has risen from $245.48 to $251.43 per share. The revision reflects updated assumptions including revenue growth moving from 12.43% to 12.68%, net profit margin adjusting from 30.23% to 29.94%, and future P/E multiple increasing from 34.48x to 35.24x. Bullish analysts from firms such as Guggenheim, Stifel, and Piper Sandler cite solid Q1 results, CRM share gains, and early AI adoption, while bearish voices from Goldman Sachs, UBS, and Citi flag AI disruption risk and CRM competition. The fair value shift signals a modest reset in how the stock is being valued amid mixed Wall Street commentary.

Veeva Systems has secured Eli Lilly and Company's commitment to deploy Veeva Vault CRM globally, while announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. The Eli Lilly win reinforces the thesis that top 20 pharma are increasingly willing to consolidate critical commercial workflows on Veeva's platform, tying directly into consensus expectations for continued subscription and services growth. Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, with the company's narrative projecting $4.7 billion revenue and $1.4 billion earnings by 2029, requiring 12.7% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today. Some analysts expect Veeva to reach about US$4.5 billion in revenue and US$1.3 billion in earnings by 2029, while the most cautious voices see AI agents, especially in Safety and clinical workflows, as a swing factor that could reshape those forecasts. The leadership change in Sales and Services does not appear to materially shift the biggest short term risk around customer concentration and contract renewals.

Eli Lilly and Company has committed to deploying Veeva Systems' Vault CRM globally, Veeva announced on August 11. Vault CRM serves as the core infrastructure for Veeva's AI-driven commercial framework, designed to modernize field engagement and speed medicine delivery. The partnership highlights how technology and drug development are becoming deeply intertwined, with Veeva as the tech engine and Eli Lilly as the pharmaceutical titan. In its fiscal 2027 first quarter, Veeva reported total revenue of $882.9 million, up 16% year-over-year, while Eli Lilly's second quarter 2026 revenue surged 48% to $22.97 billion, driven by GLP-1 therapies Mounjaro and Zepbound. Eli Lilly also raised its full-year 2026 revenue guidance to $85.0–$87.0 billion.

The global eClinical solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a compound annual growth rate of 13.98 percent, according to a report by Healthcare Foresights. The market was valued at approximately USD 11.50 billion in 2025 and is expected to reach USD 13 billion in 2026. Key players include Oracle, IQVIA, Veeva Systems, and Medidata Solution Inc. North America currently dominates the market, while the Asia-Pacific region is expected to see the highest growth rate. The report segments the market by product, delivery mode, development phase, and region.

Fundsmith Equity Fund highlighted Veeva Systems as a picks-and-shovels investment in drug development in its second-quarter 2026 investor letter. The fund noted that Veeva provides specialized cloud-based software for the pharmaceutical and life sciences industries, tracking the entire drug lifecycle from clinical trials through manufacturing and sales. Veeva holds roughly 80% market share in pharmaceutical customer relationship software, and its competitive moat is built on extremely high switching costs, as replacing the software risks halting clinical trials or drug manufacturing. Growth is fueled by upselling new modules to existing clients and using AI agents to manage administrative work in drug trials. The fund reported that Veeva's return on invested capital, excluding a large cash balance, is well in excess of 100%, with a free cash flow yield of 5.7%.

Veeva Systems raised its fiscal 2027 revenue guidance to about $3.65 billion and adjusted EPS outlook to roughly $9.05, following fiscal Q1 2027 results that exceeded its own guidance and showed stronger profitability helped by expanding AI-driven offerings. The upgrade was supported by the preview of Vault AI Agents and the Falcon agentic labor platform, which are designed to automate work in clinical operations, safety case handling, and quality documentation. The company's investment narrative now projects $4.7 billion in revenue and $1.4 billion in earnings by 2029, requiring 12.4% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today. Before the guidance hike, the most optimistic analysts were already modeling about $5.0 billion of revenue and $1.6 billion of earnings by 2029, leaning heavily on faster AI agent adoption. How quickly customers adopt these AI capabilities will likely influence whether the upgraded outlook proves conservative or ambitious.

Veeva Systems shares have gained about 7.9% since its last earnings report, outperforming the S&P 500. The company reported adjusted earnings per share of $2.24 for the first quarter of fiscal 2027, up 13.7% year over year and beating the Zacks Consensus Estimate by 5.2%. Total revenues reached $882.9 million, a 16.3% increase, driven by subscription services revenue of $730.2 million and professional services revenue of $152.8 million. For the fiscal second quarter, Veeva expects total revenues between $902 million and $905 million, with adjusted earnings per share of $2.21 to $2.22. Full-year fiscal 2027 revenue guidance was raised to between $3,635 million and $3,645 million, and adjusted earnings per share is expected to be approximately $9.05.

Stifel has reiterated its Buy rating and $230 price target on Veeva Systems following the company's acquisition of Copli. Veeva announced on June 23 the acquisition of the agentic medical, legal, and regulatory solutions firm, rebranding it as Veeva Falcon MLR, which aims to accelerate content review and potentially eliminate 70% or more of manual MLR labor within five years. The company also launched Veeva EHS on June 25, a new environmental, health, and safety application within Veeva Quality Cloud, enabling manufacturing and testing sites to manage operational and environmental risk and ensure global compliance readiness.

Shares of Guidewire Software, Veeva Systems, and Paycom surged in afternoon trading after Guggenheim analyst John DiFucci upgraded Salesforce and ServiceNow to Buy on valuation grounds, arguing that AI-disruption fears had pushed the sector too low. DiFucci, a previously cautious analyst, wrote that he was not upgrading because he sees ServiceNow as an AI beneficiary, calling near-term AI monetization unlikely and AI risks very real, but that the darkest scenario was already priced in. The read-through lifted the group, with Guidewire Software jumping 6.5%, Veeva Systems gaining 5.1%, and Paycom rising 6.2%. Oracle also added about 2% after being added to William Blair's July Analyst Conviction List and on news of a new AI product.

Veeva Systems shares rose more than 11.5% in the past week following the acquisition of Copli and the launch of the AI-driven Veeva Falcon MLR platform. On June 23, Veeva acquired Copli, a provider of agentic medical, legal, and regulatory solutions for life sciences, and made it available as Veeva Falcon MLR, aiming to reduce manual MLR labor by 70% or more within five years. On June 25, the company announced Veeva EHS, a new environmental, health, and safety application within Veeva Quality Cloud, with early adopter availability planned for August 2026. Of 29 analysts covering the stock, 20 rate it Buy and 8 rate it Hold, with an average price target of $235 implying over 37% upside. Year to date, however, the shares are down more than 23%.

Veeva Systems has acquired Copli, a pioneer in agentic medical, legal and regulatory solutions for life sciences, and simultaneously launched Veeva Falcon MLR, an AI-powered solution designed to accelerate content review and approval processes. Falcon MLR automates compliance checks against approved product labels and country-specific regulations, with the potential to eliminate more than 70% of manual MLR labor over the next five years. The solution is built on Copli's technology and integrates with Veeva PromoMats, strengthening the company's Commercial Cloud business. The acquisition expands Veeva's AI portfolio and is expected to drive customer adoption, deepen platform stickiness, and create cross-selling opportunities. Veeva currently has a market capitalization of $27.84 billion.

Veeva Systems has acquired Copli and launched Veeva Falcon MLR, an agentic medical, legal, and regulatory content-review platform now available immediately. The platform automates reviews of promotional and medical content by checking materials against approved labels and local regulations, with the potential to eliminate more than 70% of manual MLR work over the next five years. Copli CEO Jacob Scheel-Bech called the launch a fundamental shift in content review, noting the acquisition will help scale the company's vision for AI-focused MLR while merging its technology with Veeva PromoMats. Emma Hyland, vice president of Veeva Commercial Content, said the MLR process has long slowed the delivery of information to patients and physicians, and that Veeva Falcon MLR can shorten review cycles by automating routine work, allowing reviewers to focus on higher-value responsibilities.

Veeva Systems has launched Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud, designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness. The solution enables real-time safety incident reporting, end-to-end investigation management, and automated compliance workflows, integrating with Veeva QMS and Veeva Training to automatically create quality deviations and assign relevant training. Veeva EHS is expected to be available to early adopters in August 2026. The environmental health and safety software market is valued at 8.9 billion dollars in 2026 and is projected to grow at a compound annual growth rate of 8.1 percent through 2030, driven by stringent regulatory requirements, digital transformation, and the integration of artificial intelligence and machine learning.

Brown Capital Management’s Small Company Fund argues that Veeva Systems is relatively well insulated from AI-driven disruption because its cloud-based software is deeply embedded in specialized regulatory, clinical, and commercial workflows for the life sciences industry. The fund notes that Veeva’s platform relies on proprietary, highly structured data tied to drug development and compliance, making it less susceptible to commoditization by AI trained on public data. It also highlights that Veeva operates as a system of record for regulated content, unlike more easily disrupted interface-driven systems of engagement. Despite these defensive qualities, the stock is trading at a 55% discount to its historical price-to-sales ratio, which the fund attributes largely to an AI-related derating. Veeva Systems closed at $159.71 per share on June 23, 2026, with a market capitalization of $25.94 billion, and its shares have lost 42.86% over the past 52 weeks.

The global pharmacovigilance automation market is projected to grow from USD 2.80 billion in 2025 to USD 5.25 billion by 2035, at a compound annual growth rate of 6.50 percent. Software held a 72.40 percent share of the market in 2025, while the services segment is the fastest growing at a CAGR of 8.77 percent. Cloud-based deployment accounted for 49.80 percent of the market in 2025, and the SaaS segment is expected to record the highest CAGR of 13.02 percent. Artificial intelligence dominated with a 41.30 percent share in 2025, and natural language processing is the fastest growing technology segment at a CAGR of 13.73 percent. Pharmaceutical companies led end users with a 58.60 percent share in 2025, while biotechnology companies are the fastest growing at a CAGR of 11.57 percent. North America held a 38.60 percent share of the global market in 2025, and the Asia-Pacific region is the fastest growing regional market with a CAGR of about 8.92 percent.

Veeva Systems reported strong first-quarter results for fiscal 2027, with total revenues climbing 16% year-over-year to $882.9 million and subscription revenues rising 15% to $730.2 million, exceeding its own guidance across all metrics and prompting an increase in its full-year financial outlook. The company is advancing a strategic shift toward becoming an AI agent company, integrating conversational AI through its acquisition of Ostro, expanding Vault AI, and planning an early adopter release of Veeva Falcon in November, a platform designed to deliver agentic labor for clinical, regulatory, and safety workflows. Its commercial momentum continued with 27 new Vault CRM customers added in the quarter, pushing total live implementations past 150.

Nvidia CEO Jensen Huang stated at a recent technology trade show that it is a great time to be a software company, arguing that artificial intelligence will improve their products and services rather than replace them. Veeva Systems, a SaaS leader for the life sciences sector, reported fiscal first-quarter revenue of $882.9 million, up 16% year over year, and launched Veeva AI, an agentic AI system. Adobe posted record second-quarter revenue of $6.62 billion, a 13% increase, with AI-first annualized recurring revenue surpassing $500 million, a threefold year-over-year jump. Both stocks have declined recently but maintain strong competitive advantages and are incorporating AI into their offerings.